Grifols Secures 95% of Investor Support to Improve Documentation Terms of Its €1.3 Billion 7.5% Secured Notes
Download PDF
Barcelona, November 12, 2025. Grifols, S.A. (MCE: GRF, NASDAQ: GRFS), a global leader in plasma-derived medicines and innovative healthcare solutions, today announced that almost the 95% of bond investors holding its €1.3 billion 7.5% Senior Secured Notes due 2030 have approved the proposed amendment to the notes' indenture, exceeding the required majority well ahead of the deadline.
The strong level of support follows the company's recent consent solicitation process, which sought approval to align certain provisions of the 7.5% Notes and the Indenture with those governing the Company's more recently issued 7.125% Senior Secured Notes due 2030, ensuring greater consistency across its capital structure and enhancing the company's overall financial flexibility.
Rahul Srinivasan, CFO of Grifols, said: "The successful bondholder consent solicitation exercise not only further validates institutional investors' strong confidence in Grifols but, importantly, also increases Grifols' flexibility with regards to the refinancing plans we referenced in our Q3 results presentation."
Attachments
Original document
Permalink
Disclaimer
Grifols SA published this content on November 12, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 12, 2025 at 17:09 UTC.
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows:
- products derived from plasma (85.2%): products for use by the pharmaceutical and biotechnology industries;
- diagnostic machines and reagents (8.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers;
- hospital products (3%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies;
- other (2.9%): primarily intermediate biological products and subcontracted manufacturing services.
Net sales are distributed geographically as follows: Spain (5.9%), European Union (15.5%), the United States and Canada (56.7%) and other (21.9%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
